WellDyneRx, an independent Pharmacy Benefit Manager involved in delivering solutions through integrated data and technology, has named Jeff Park as its new chairman and chief executive officer of the company, it was reported yesterday.
Park is the former executive vice president and chief operating officer of Catamaran, which is now called optumRx. During his tenure, Catamaran grew from USD55m in revenues to a Fortune 500 public company with over USD21bn in revenues before it was acquired by United Health Group in 2015.
WellDyneRx lead director, Eric Elliott, said, 'We are excited to have Jeff join WellDyneRx president, Zach Johnson, and the rest of our leadership team. Jeff's strategic vision and operating expertise support our growth plans. Our extensive search for the right executive produced a great result. Now, with a strong team in place, we expect our value proposition in the constantly changing PBM sector to resonate even more clearly, and growth will accelerate.'
AMGEN announces Q3 2026 dividend
West Pharmaceutical Services declares quarterly dividend of USD0.22 per share
MedPal AI acquires eMARx to expand digital care home platform
Valerio Therapeutics signs R&D collaboration with Abivax and outlines pipeline milestones
Aptamer Group launches Optimer-based Ebola diagnostic programme
SK bioscience to lead Gates Foundation-funded ROTOR project
Nona Biosciences and Lonza collaborate on antibody-based BBB-crossing technology for CNS diseases
Gilead Sciences mobilises remdesivir donation to support Ebola response in Uganda
INOVIO's oartner ApolloBio reports positive topline results from Phase 3 trial of VGX-3100
Lilly declares Q2 2026 dividend
Collegium to acquire AZSTARYS from Corium Therapeutics
CVS Health announces quarterly dividend of USD0.665 per share